Investigation of Single Rising Doses of BI 685509
- Conditions
- Healthy
- Interventions
- Drug: BI 685509Drug: Placebo
- First Posted Date
- 2016-02-29
- Last Posted Date
- 2016-05-04
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 16
- Registration Number
- NCT02694354
- Locations
- 🇩🇪
1366.1.1 Boehringer Ingelheim Investigational Site, Biberach, Germany
SATisfaction and Adherence to COPD Treatment
- Conditions
- Pulmonary Disease, Chronic Obstructive
- First Posted Date
- 2016-02-24
- Last Posted Date
- 2019-08-28
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 401
- Registration Number
- NCT02689492
- Locations
- 🇮🇹
Asst Santi Paolo E Carlo, Milano, Italy
🇮🇹Ospedale Reg Umberto Parini, Aosta, Italy
🇮🇹ASL 4 di Terni, Terni, Italy
Weekly BI 836880 in Patients With Advanced Solid Tumors
- Conditions
- Neoplasms
- Interventions
- Drug: BI 836880
- First Posted Date
- 2016-02-24
- Last Posted Date
- 2019-09-04
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 24
- Registration Number
- NCT02689505
- Locations
- 🇪🇸
Hospital Vall d'Hebron, Barcelona, Spain
🇫🇷CTR Georges-François Leclerc, Dijon, France
Patient Convenience Study (RE-SONANCE)
- Conditions
- Atrial FibrillationStroke
- First Posted Date
- 2016-02-18
- Last Posted Date
- 2019-07-24
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 9472
- Registration Number
- NCT02684981
Fixed Dose Combination Versus Free Combination of Tiotropium and Olodaterol in COPD
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- First Posted Date
- 2016-02-17
- Last Posted Date
- 2018-08-17
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 221
- Registration Number
- NCT02683109
- Locations
- 🇦🇹
Ordination Dr. Robert Voves, 8330 Feldbach, Feldbach, Austria
🇦🇹KH d. Elisabethinen Linz, Linz, Austria
🇩🇰Aarhus Universitetshospital, Aarhus, Denmark
Assessment of Physical Functioning and Handling of Spiolto® Respimat® in Patients With Chronic Obstructive Pulmonary Disease (COPD) Requiring Long-acting Dual Bronchodilation in Routine Clinical Practice
- First Posted Date
- 2016-02-05
- Last Posted Date
- 2018-10-15
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 1737
- Registration Number
- NCT02675517
Dose Finding Study of BI 836880 in Patients With Solid Tumors
- Conditions
- Neoplasms
- Interventions
- Drug: BI 836880
- First Posted Date
- 2016-02-04
- Last Posted Date
- 2021-09-08
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 29
- Registration Number
- NCT02674152
- Locations
- 🇩🇪
Universitätsklinikum Freiburg, Freiburg, Germany
🇩🇪Universitätsklinikum Augsburg, Augsburg, Germany
🇫🇷INS Curie, Paris, France
LUME BioNIS: a Biomarker Study in Patients With NSCLC
- Conditions
- Carcinoma, Non-Small-Cell Lung
- First Posted Date
- 2016-02-02
- Last Posted Date
- 2020-09-24
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 260
- Registration Number
- NCT02671422
- Locations
- 🇪🇸
Hospital de León, León, Spain
🇧🇪Charleroi - UNIV CHU de Charleroi, Lodelinsart, Belgium
🇧🇪AZ Maria Middelares, Gent, Belgium
Nintedanib and Weekly Docetaxel in Lung Adenocarcinoma
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- First Posted Date
- 2016-01-29
- Last Posted Date
- 2021-01-29
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 14
- Registration Number
- NCT02668393
- Locations
- 🇫🇷
HOP d'Angers, Angers, France
🇫🇷HOP Jean Minjoz, Besançon, France
🇩🇪Pneumologisches Forschungsinstitut an der LungenClinic Grosshansdorf GmbH, Großhansdorf, Germany
Influence of Bosentan on the Pharmacokinetics of Nintedanib
- First Posted Date
- 2016-01-29
- Last Posted Date
- 2017-04-13
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 13
- Registration Number
- NCT02667704
- Locations
- 🇩🇪
Boehringer Ingelheim Investigational Site, Biberach, Germany